Aura Biosciences, Inc.
AURA
Jodie situation report
Aura Biosciences, Inc.'s move is spreading beyond its market group.
No new filing conclusion is available. 23 of 23 group members are active now; 1 filing-linked outsider is moving with the group, and 0 of 1 directly disclosed connection is confirming.
- At least 15 of 23 members remain active in the next snapshot.
- Capital-flow agreement rises above 55%.
- BMRN remains aligned with the group in the next market snapshot.
Invalidation: The live read weakens if participation falls to 8 of 23 members or fewer.
Who this business touches
The relationships behind AURA
Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.
Depended on by
URGNUroGen Pharma Ltd.competitorMar 2, 2026 ▾
“We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…”
Filing peers
Companies whose filings use similar operating language.
Open the three relationships above to see Jodie’s filing proof. Pro unlocks 2 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →
What is moving around it
Live connections
AURA is currently a Participant in the organic co-movement group Clinical Biotechnology. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 1 filing-linked name are in the relationship map; none is currently confirmed as moving with the group.